Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER Study: Vibegron Effects on Night-time Frequency and Sleep Quality in Overactive Bladder
jRCTs031250406Active, not recruiting
- Sponsor
- Kyorin Pharmaceutical
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vibegron in overactive bladder (OAB), sponsored by Kyorin Pharmaceutical. Primary endpoint: Primary endpoint: Change in night-time frequency at 12 weeks. Started Oct 2025; status: active, not recruiting.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on jRCTs031250406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250406.